קרדיוקסאן - Cardioxane
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | V03AF Detoxifying agents for antineoplastic treatment | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | ת××-×ר××× - I.V | |||||||||||||
| צ×רת ××× ×× | ×××§× ×××× ×ª ת×××¡× ×××× ×¤××××, POWDER FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | Prevention of cardiotoxicity in adult women with advanced and/or metastatic breast cancer at high risk of heart failure who have received a prior cumulative dose of 300 mg/m2 of doxorubicin or a prior cumulative dose of 540 mg/m2 of epirubicin when further anthracycline treatment is required.
| |||||||||||||
| ||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 Â
| |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| קר×××קס×× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | CENEXI - LABORATOIRES THISSEN SA., BELGIUM |
| ×©× ××¢× ×ר×ש×× | MEGAPHARM LTD |
| ר×ש××× | ת×ר×× ××ש×: 11/1997. ר×ש××× ×ת×ר××: 03/2013 |
| ת×ר×× ×¢×××× ××ר×× | 13/03/24 |
× ×ª×× × ×¡×
| × ×ª×× × ××¡× | |||||||
|---|---|---|---|---|---|---|---|
ת×ר×× ××××× ×ס×
| |||||||
×××××ת ×ס×
| |||||||
×ת×××× ×ס×
| |||||||
| ש×××ש ×ס×
| |||||||
×ס×רת ××××× ×ס×
|
השינוי האחרון נעשה בֹ־28 בדצמבר 2013 ב־17:50